{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T21:07:13Z","timestamp":1786655233320,"version":"build-2736575974"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s43440-025-00803-9","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:36:54Z","timestamp":1761629814000},"page":"90-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Upadacitinib as rescue therapy for acute severe ulcerative colitis and severe Crohn\u2019s disease \u2013 current knowledge and future directions"],"prefix":"10.1007","volume":"78","author":[{"given":"Mi\u0142osz","family":"Caban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Strig\u00e1\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Sza\u0142wi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Talar-Wojnarowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"803_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.25122\/jml-2018-0075","volume":"12","author":"SS Seyedian","year":"2019","unstructured":"Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12:113\u201322.","journal-title":"J Med Life"},{"key":"803_CR2","doi-asserted-by":"publisher","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","volume":"13","author":"R Wang","year":"2023","unstructured":"Wang R, Li Z, Liu S, Zhang D. Global, regional and National burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019. BMJ Open. 2023;13:e065186.","journal-title":"BMJ Open"},{"key":"803_CR3","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1186\/s12889-023-17431-8","volume":"23","author":"JL Zhou","year":"2023","unstructured":"Zhou JL, Bao JC, Liao XY, Chen YJ, Wang LW, Fan YY, et al. Trends and projections of inflammatory bowel disease at the global, regional and National levels, 1990\u20132050: a bayesian age-period-cohort modeling study. BMC Public Health. 2023;23:2507.","journal-title":"BMC Public Health"},{"key":"803_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","volume":"18","author":"GG Kaplan","year":"2021","unstructured":"Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"803_CR5","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/ueg2.12442","volume":"11","author":"L Calm\u00e9jane","year":"2023","unstructured":"Calm\u00e9jane L, Laharie D, Kirchgesner J, Uzzan M. Review article: updated management of acute severe ulcerative colitis: from steroids to novel medical strategies. United Eur Gastroenterol J. 2023;11:722\u201332.","journal-title":"United Eur Gastroenterol J"},{"key":"803_CR6","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1136\/gutjnl-2024-332489","volume":"73","author":"S Honap","year":"2024","unstructured":"Honap S, Jairath V, Sands BE, Dulai PS, Danese S, Peyrin-Biroulet L. Acute severe ulcerative colitis trials: the past, the present and the future. Gut. 2024;73:1763\u201373.","journal-title":"Gut"},{"key":"803_CR7","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","volume":"17","author":"JP Gisbert","year":"2023","unstructured":"Gisbert JP, Garc\u00eda MJ, Chaparro M. Rescue therapies for Steroid-refractory acute severe ulcerative colitis: A review. J Crohns Colitis. 2023;17:972\u201394.","journal-title":"J Crohns Colitis"},{"key":"803_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.5009\/gnl220017","volume":"17","author":"H Nakase","year":"2023","unstructured":"Nakase H. Acute severe ulcerative colitis: optimal strategies for drug therapy. Gut Liver. 2023;17:49\u201357.","journal-title":"Gut Liver"},{"key":"803_CR9","doi-asserted-by":"publisher","first-page":"e611","DOI":"10.1097\/MJT.0000000000001280","volume":"29","author":"AV Patel","year":"2022","unstructured":"Patel AV, Moore J, Sultan K. Infliximab as rescue therapy for hospitalized patients with crohn\u2019s disease failing intravenous corticosteroids. Am J Ther. 2022;29:e611\u20135.","journal-title":"Am J Ther"},{"key":"803_CR10","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1177\/00031348241246160","volume":"90","author":"AE Whitlock","year":"2024","unstructured":"Whitlock AE, Arndt KR, Zakopoulos I, Wong DJ, Kaul S, Feuerstein J, et al. Safety and efficacy of inpatient Infliximab rescue therapy for acute crohn\u2019s disease flares. Am Surg. 2024;90:1591\u20138.","journal-title":"Am Surg"},{"key":"803_CR11","first-page":"415","volume":"32","author":"E Sinagra","year":"2018","unstructured":"Sinagra E, Orlando A, Mocciaro F, Criscuoli V, Oliva L, Maisano S, et al. Clinical course of severe colitis: a comparison between crohn\u2019s disease and ulcerative colitis. J Biol Regul Homeost Agents. 2018;32:415\u201323.","journal-title":"J Biol Regul Homeost Agents"},{"key":"803_CR12","doi-asserted-by":"publisher","first-page":"jjaf021","DOI":"10.1093\/ecco-jcc\/jjaf021","volume":"19","author":"JP Gisbert","year":"2025","unstructured":"Gisbert JP, Chaparro M. Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review. J Crohns Colitis. 2025;19:jjaf021.","journal-title":"J Crohns Colitis"},{"key":"803_CR13","doi-asserted-by":"publisher","first-page":"e13688","DOI":"10.1111\/cts.13688","volume":"17","author":"MF Mohamed","year":"2024","unstructured":"Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P, Upadacitinib. Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17:e13688.","journal-title":"Clin Transl Sci"},{"key":"803_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","volume":"14","author":"AM Shawky","year":"2022","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14:1001.","journal-title":"Pharmaceutics"},{"key":"803_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402.","journal-title":"Signal Transduct Target Ther"},{"key":"803_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41392-024-01975-1","volume":"9","author":"Y Lv","year":"2024","unstructured":"Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, et al. The JAK-STAT pathway: from structural biology to cytokine engineering. Signal Transduct Target Ther. 2024;9:290.","journal-title":"Signal Transduct Target Ther"},{"key":"803_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical Inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, Tofacitinib and baricitinib. Ann Rheum Dis. 2021;80:865\u201375.","journal-title":"Ann Rheum Dis"},{"key":"803_CR18","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.3390\/jcm13164678","volume":"13","author":"A Strig\u00e1\u010d","year":"2024","unstructured":"Strig\u00e1\u010d A, Caban M, Ma\u0142ecka-Wojciesko E, Talar-Wojnarowska R. Safety and effectiveness of thiopurines and small molecules in elderly patients with inflammatory bowel diseases. J Clin Med. 2024;13:4678.","journal-title":"J Clin Med"},{"key":"803_CR19","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP, Peyrin-Biroulet L, D\u2019Haens G, Panaccione R, et al. Upadacitinib induction and maintenance therapy for crohn\u2019s disease. N Engl J Med. 2023;388:1966\u201380.","journal-title":"N Engl J Med"},{"key":"803_CR20","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3390\/jcm14051695","volume":"14","author":"M Kaniewska","year":"2025","unstructured":"Kaniewska M, Lewandowski K, Krogulecki M, Filipiuk A, Gonciarz M, Pietrzak A, et al. Efficacy of Upadacitinib induction treatment in Moderate-to-Severe ulcerative colitis including intestinal ultrasound assessment: A Multicenter, Real-World observational study. J Clin Med. 2025;14:1695.","journal-title":"J Clin Med"},{"key":"803_CR21","doi-asserted-by":"publisher","first-page":"101866","DOI":"10.1016\/j.eclinm.2023.101866","volume":"57","author":"M Attauabi","year":"2023","unstructured":"Attauabi M, Dahl EK, Burisch J, Gubatan J, Nielsen OH, Seidelin JB. Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. EClinicalMedicine. 2023;57:101866.","journal-title":"EClinicalMedicine"},{"key":"803_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1208\/s12248-019-0378-y","volume":"21","author":"MF Mohamed","year":"2019","unstructured":"Mohamed MF, Trueman S, Othman AA, Han JH, Ju TR, Marroum P. Development of in Vitro-In vivo correlation for Upadacitinib Extended-Release tablet formulation. AAPS J. 2019;21:108.","journal-title":"AAPS J"},{"key":"803_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","volume":"59","author":"MF Mohamed","year":"2020","unstructured":"Mohamed MF, Kl\u00fcnder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet. 2020;59:531\u201344.","journal-title":"Clin Pharmacokinet"},{"key":"803_CR24","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","volume":"21","author":"S Friedberg","year":"2023","unstructured":"Friedberg S, Choi D, Hunold T, Choi NK, Garcia NM, Picker EA, et al. Upadacitinib is effective and safe in both ulcerative colitis and crohn\u2019s disease: prospective Real-World experience. Clin Gastroenterol Hepatol. 2023;21:1913\u2013e19232.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"803_CR25","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/00042737-199810000-00003","volume":"10","author":"SC Lindgren","year":"1998","unstructured":"Lindgren SC, Flood LM, Kilander AF, L\u00f6fberg R, Persson TB, Sj\u00f6dahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10:831\u20135.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"803_CR26","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/apt.13614","volume":"43","author":"RW Lynch","year":"2016","unstructured":"Lynch RW, Churchhouse AM, Protheroe A, Arnott ID; UK IBD Audit Steering Group. Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data. Aliment Pharmacol Ther. 2016;43:1132\u201341.","journal-title":"Aliment Pharmacol Ther"},{"key":"803_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ecco-jcc\/jjab177","volume":"16","author":"A Spinelli","year":"2022","unstructured":"Spinelli A, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment. J Crohns Colitis. 2022;16:179\u201389.","journal-title":"J Crohns Colitis"},{"key":"803_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gut.38.6.905","volume":"38","author":"SP Travis","year":"1996","unstructured":"Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905\u201310.","journal-title":"Gut"},{"key":"803_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/ajg.2016.7","volume":"111","author":"N Narula","year":"2016","unstructured":"Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, et al. Systematic review and Meta-Analysis: Infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol. 2016;111:477\u201391.","journal-title":"Am J Gastroenterol"},{"key":"803_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","volume":"1","author":"JG Williams","year":"2016","unstructured":"Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1:15\u201324.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"803_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","volume":"5","author":"D Turner","year":"2007","unstructured":"Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103\u201310.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"803_CR32","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S2468-1253(24)00200-0","volume":"9","author":"MC Choy","year":"2024","unstructured":"Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, et al. Intensified versus standard dose Infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9:981\u201396.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"803_CR33","doi-asserted-by":"publisher","first-page":"7446","DOI":"10.3390\/jcm13237446","volume":"13","author":"E Ong Ming San","year":"2024","unstructured":"Ong Ming San E, Sharif K, Rosiou K, Rennie M, Selinger CP. Recent advances in the management of acute severe ulcerative colitis. J Clin Med. 2024;13:7446.","journal-title":"J Clin Med"},{"key":"803_CR34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of crohn\u2019s disease in adults. Am J Gastroenterol. 2018;113:481\u2013517.","journal-title":"Am J Gastroenterol"},{"key":"803_CR35","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, et al. ECCO guidelines on therapeutics in crohn\u2019s disease: medical treatment. J Crohns Colitis. 2024;18:1531\u201355.","journal-title":"J Crohns Colitis"},{"key":"803_CR36","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/ibd\/izae191","volume":"31","author":"JA Damianos","year":"2025","unstructured":"Damianos JA, Osikoya O, Brennan G. Upadacitinib for acute severe ulcerative colitis: A systematic review. Inflamm Bowel Dis. 2025;31:1145\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"803_CR37","doi-asserted-by":"publisher","first-page":"e940966","DOI":"10.12659\/AJCR.940966","volume":"24","author":"NM Ali","year":"2023","unstructured":"Ali NM, Shehab MA. Upadacitinib as a rescue therapy in acute severe ulcerative colitis: A case report and review of the literature. Am J Case Rep. 2023;24:e940966.","journal-title":"Am J Case Rep"},{"key":"803_CR38","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/jgh3.13015","volume":"7","author":"P Hilley","year":"2023","unstructured":"Hilley P, Con D, Choy MC, Srinivasan A, De Cruz P. Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis. JGH Open. 2023;7:1012\u20135.","journal-title":"JGH Open"},{"key":"803_CR39","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s12328-024-01976-1","volume":"17","author":"N Nakamura","year":"2024","unstructured":"Nakamura N, Honzawa Y, Ohtsu T, Sano Y, Ito Y, Fukata N, et al. Efficacy of Upadacitinib in the achievement of clinical and endoscopic remission in hospitalized patients with ulcerative colitis. Clin J Gastroenterol. 2024;17:654\u20137.","journal-title":"Clin J Gastroenterol"},{"key":"803_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14744\/Jenterocolitis.2024.25417","volume":"3","author":"B \u00d6zkart","year":"2024","unstructured":"\u00d6zkart B, Kabao\u011flu C, Danac\u0131 H\u00c7, I\u015f\u0131k E, \u00dcnal NG. Rescue therapy with Upadacitinib for Infliximab-Refractory acute severe ulcerative colitis patient: A case report and mini review of the literature. J Entercolitis. 2024;3:55\u20137.","journal-title":"J Entercolitis"},{"key":"803_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000542711","volume":"19","author":"D Huynh","year":"2024","unstructured":"Huynh D, Khaing MM, Fernandes RG, Malloy R, Lin L, Gilmore R, et al. Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case report. Case Rep Gastroenterol. 2024;19:1\u20136.","journal-title":"Case Rep Gastroenterol"},{"key":"803_CR42","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ibd\/izae146","volume":"31","author":"SA Urquhart","year":"2025","unstructured":"Urquhart SA, Chedid VG, Kane SV. Use of Upadacitinib as salvage therapy for ulcerative colitis in pregnancy: A case report. Inflamm Bowel Dis. 2025;31:300\u20131.","journal-title":"Inflamm Bowel Dis"},{"key":"803_CR43","doi-asserted-by":"crossref","unstructured":"Geeganage G, Flynn DJ, Martinez S, Wang MJ, Spiel M, Rabinowitz LG, et al. Upadacitinib as rescue therapy in a pregnant patient with IBD. ACG Case Rep J. 2025;12:e01701.","DOI":"10.14309\/crj.0000000000001701"},{"key":"803_CR44","doi-asserted-by":"publisher","unstructured":"Berinstein JA, Karl T, Patel A, Dolinger M, Barrett TA, Ahmed W, et al. Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience. Am J Gastroenterol. 2024. https:\/\/doi.org\/10.14309\/ajg.0000000000002674.","DOI":"10.14309\/ajg.0000000000002674"},{"key":"803_CR45","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s10620-024-08302-2","volume":"69","author":"J Clinton","year":"2024","unstructured":"Clinton J, Motwani KK, Schwartz S, McCarthy P, Axelrad JE, Cross RK, et al. Upadacitinib as rescue therapy for the treatment of acute severe colitis in an acute care setting. Dig Dis Sci. 2024;69:1105\u20139.","journal-title":"Dig Dis Sci"},{"key":"803_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00384-025-04825-w","volume":"40","author":"C-S Chung","year":"2025","unstructured":"Chung C-S, Lee W-W, Le P-H. Upadacitinib as rescue therapy for corticosteroid failure acute severe ulcerative colitis: an Asian experience from Taiwan. Int J Colorectal Dis. 2025;40:33.","journal-title":"Int J Colorectal Dis"},{"key":"803_CR47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10238-024-01468-z","volume":"24","author":"J Zhang","year":"2024","unstructured":"Zhang J, Li R, Chen L, Wang F, Zhou H, Liu X, et al. Effectiveness and safety of Upadacitinib in acute severe ulcerative colitis patients from single Chinese IBD center: a monocentric study. Clin Exp Med. 2024;24:233.","journal-title":"Clin Exp Med"},{"key":"803_CR48","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1093\/ecco-jcc\/jjad115","volume":"17","author":"R Gilmore","year":"2023","unstructured":"Gilmore R, Tan WL, Fernandes R, An YK, Begun J. Upadacitinib salvage therapy for Infliximab-Experienced patients with acute severe ulcerative colitis. J Crohns Colitis. 2023;17:2033\u20136.","journal-title":"J Crohns Colitis"},{"key":"803_CR49","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/ibd\/izad180","volume":"29","author":"CH Zinger","year":"2023","unstructured":"Zinger CH, Ringel Y, Eitan M, Openhaim M, Kayless H, Stein A, et al. Upadacitinib for acute severe ulcerative colitis. Inflamm Bowel Dis. 2023;29:1667\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"803_CR50","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ibd\/izae038","volume":"30","author":"RS Dalal","year":"2024","unstructured":"Dalal RS, Winter RW, Gupta S, Sasson GF, Hamilton MJ, Allegretti JR. Clinical outcomes at 8\u201316 weeks after Upadacitinib initiation for acute severe ulcerative colitis: A case series in the united States. Inflamm Bowel Dis. 2024;30:1042\u20133.","journal-title":"Inflamm Bowel Dis"},{"key":"803_CR51","doi-asserted-by":"publisher","first-page":"175628482513235","DOI":"10.1177\/17562848251323511","volume":"18","author":"A Etchegaray","year":"2025","unstructured":"Etchegaray A, Tambakis G, Kumar R, Croft A, Radford-Smith G, Walker GJ. Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series. Th Adv Gastroenterol. 2025;18:17562848251323511.","journal-title":"Th Adv Gastroenterol"},{"issue":"10S","key":"803_CR52","doi-asserted-by":"publisher","first-page":"S2142","DOI":"10.14309\/01.ajg.0000962504.98929.1c","volume":"118","author":"CM Anand","year":"2023","unstructured":"Anand CM, Gandhi S. S3216 upadacitinib - a treatment alternative for severe ulcerative colitis in the hospital. Am J Gastroenterol. 2023;118(10S):S2142. https:\/\/doi.org\/10.14309\/01.ajg.0000962504.98929.1c.","journal-title":"Am J Gastroenterol"},{"issue":"10S","key":"803_CR53","doi-asserted-by":"publisher","first-page":"S2116","DOI":"10.14309\/01.ajg.0000962320.66241.35","volume":"118","author":"A Madej","year":"2023","unstructured":"Madej A, Vedamurthy A, Taleban S. S3170 JAK(1i) to the rescue! Upadacitinib as rescue therapy in acute severe ulcerative colitis. Am J Gastroenterol. 2023;118(10S):S2116\u20132116.","journal-title":"Am J Gastroenterol"},{"issue":"10S","key":"803_CR54","doi-asserted-by":"publisher","first-page":"S2138","DOI":"10.14309\/01.ajg.0000962468.27189.00","volume":"118","author":"CP Martyn","year":"2023","unstructured":"Martyn CP, Boroda K. P2231 induction of remission in TNF alpha inhibitor refractory acute severe ulcerative colitis with upadacitinib: a case report. Am J Gastroenterol. 2023;118(10S):S2138\u20132138.","journal-title":"Am J Gastroenterol"},{"issue":"12S","key":"803_CR55","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.14309\/01.ajg.0000995872.32570.7e","volume":"118","author":"L Shipley","year":"2023","unstructured":"Shipley L, Russ K, Zahid M, Ismail M. S34 intestinal ultrasound to assess clinical response after induction with Upadacitinib in acute severe ulcerative colitis. Am J Gastroenterol. 2023;118(12S):S10\u201310.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"803_CR56","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1053\/j.gastro.2023.11.281","volume":"166","author":"SA Hassan","year":"2024","unstructured":"Hassan SA, Perry C, Flomenhoft D, Richardson B, Kapur N, Berinstein J, et al. Upadacitinib as second- and third-line salvage therapy for refractory acute severe ulcerative colitis. Gastroenterology. 2024;166(3):S124\u20135.","journal-title":"Gastroenterology"},{"key":"803_CR57","doi-asserted-by":"publisher","first-page":"i1877","DOI":"10.1093\/ecco-jcc\/jjae190.1189","volume":"19","author":"N \u00dcnal G\u00fclsen","year":"2025","unstructured":"\u00dcnal G\u00fclsen N, Bakkaloglu OK, Kav T, Kani HT, Akpinar A, Akincioglu P, et al. P1015 Upadacitinib as a rescue therapy in patients with Steroid- and Infliximab-Refractory acute severe ulcerative colitis: Real-Life multicentre results. J Crohns Colitis. 2025;19:i1877\u20138.","journal-title":"J Crohns Colitis"},{"key":"803_CR58","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.cgh.2024.02.027","volume":"22","author":"JF Colombel","year":"2024","unstructured":"Colombel JF, Hisamatsu T, Atreya R, Bresso F, Thin L, Panaccione R, et al. Upadacitinib reduces crohn\u2019s disease symptoms within the first week of induction therapy. Clin Gastroenterol Hepatol. 2024;22:1668\u201377.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"803_CR59","doi-asserted-by":"publisher","first-page":"otae060","DOI":"10.1093\/crocol\/otae060","volume":"360","author":"C Bezzio","year":"2024","unstructured":"Bezzio C, Franchellucci G, Savarino EV, Mastronardi M, Caprioli FA, Bodini G, et al. Upadacitinib in patients with Difficult-to-Treat crohn\u2019s disease. Crohns Colitis. 2024;360:6:otae060.","journal-title":"Crohns Colitis"},{"key":"803_CR60","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.14309\/ajg.0000000000002676","volume":"119","author":"G Dragoni","year":"2024","unstructured":"Dragoni G, Innocenti T, Amiot A, Castiglione F, Melotti L, Festa S, et al. Rates of adverse events in patients with ulcerative colitis undergoing colectomy during treatment with Tofacitinib vs biologics: A multicenter observational study. Am J Gastroenterol. 2024;119:1525\u201335.","journal-title":"Am J Gastroenterol"},{"key":"803_CR61","doi-asserted-by":"publisher","first-page":"S914","DOI":"10.14309\/01.ajg.0001034492.50788.f5","volume":"119","author":"A Sohail","year":"2024","unstructured":"Sohail A, Sinh P, Bhinder M, Cooper G, Nguyen V, Katz J, Cominelli F, et al. S1281 evaluating the safety of JAK inhibitors in ulcerative colitis patients undergoing colectomy: A propensity Score-Matched analysis. Am J Gastroenterol. 2024;119:S914.","journal-title":"Am J Gastroenterol"},{"key":"803_CR62","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/ecco-jcc\/jjad100","volume":"17","author":"V Solitano","year":"2023","unstructured":"Solitano V, Vuyyuru SK, MacDonald JK, Zayadi A, Parker CE, Narula N, et al. Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and Meta-Analysis. J Crohns Colitis. 2023;17:1800\u201316.","journal-title":"J Crohns Colitis"},{"key":"803_CR63","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1080\/17512433.2021.1925536","volume":"14","author":"R Fischer-Betz","year":"2021","unstructured":"Fischer-Betz R, \u00d8stensen M. Biologics and small molecules in the management of psoriatic arthritis: reproduction related issues in female and male patients. Expert Rev Clin Pharmacol. 2021;14:979\u201389.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"803_CR64","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40264-024-01454-0","volume":"47","author":"U Mahadevan","year":"2024","unstructured":"Mahadevan U, Levy G, Gensler L, Ali M, Lacerda AP, Wegrzyn L, et al. Pregnancy outcomes in patients treated with upadacitinib: analysis of data from clinical trials and postmarketing reports. Drug Saf. 2024;47:1039\u201349.","journal-title":"Drug Saf"},{"key":"803_CR65","doi-asserted-by":"publisher","first-page":"175628482412997","DOI":"10.1177\/17562848241299737","volume":"17","author":"C Selinger","year":"2024","unstructured":"Selinger C, Laube R, Limdi JK, Headley K, Kent A, Kok K, et al. Appropriateness of small molecule agents for patients with IBD of childbearing age - a RAND\/UCLA appropriateness panel. Th Adv Gastroenterol. 2024;17:17562848241299737.","journal-title":"Th Adv Gastroenterol"},{"key":"803_CR66","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.3748\/wjg.v29.i16.2469","volume":"29","author":"D Subhaharan","year":"2023","unstructured":"Subhaharan D, Ramaswamy PK, Willmann L, Moattar H, Bhullar M, Ishaq N, et al. Older adults with acute severe ulcerative colitis have similar steroid non-response and colectomy rates as younger adults. World J Gastroenterol. 2023;29:2469\u201378.","journal-title":"World J Gastroenterol"},{"key":"803_CR67","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/ecco-jcc\/jjad183","volume":"18","author":"T Boyd","year":"2024","unstructured":"Boyd T, Araka EB, Kochar B, Ananthakrishnan AN. Differences in management and outcomes of older and younger adults with acute severe ulcerative colitis. J Crohns Colitis. 2024;18:570\u20137.","journal-title":"J Crohns Colitis"},{"key":"803_CR68","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other Immune-mediated diseases: A systematic review and Meta-Analysis. Gastroenterology. 2020;158:1554\u201373.","journal-title":"Gastroenterology"},{"key":"803_CR69","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/25785826.2023.2183594","volume":"46","author":"H Kameda","year":"2023","unstructured":"Kameda H. JAK inhibitors \u223c overview\u223c. Immunol Med. 2023;46:108\u201311.","journal-title":"Immunol Med"},{"key":"803_CR70","first-page":"250","volume":"60","author":"K Dutt","year":"2024","unstructured":"Dutt K, Vasudevan A. Therapeutic drug monitoring for biologic and Small-Molecule therapies for inflammatory bowel disease. Med (Kaunas). 2024;60:250.","journal-title":"Med (Kaunas)"},{"key":"803_CR71","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ard.2025.05.536","volume":"84","author":"J Tachet","year":"2025","unstructured":"Tachet J, Dumusc A, Juillerat P, Conrad C, Caplanusi T, Bardinet C, et al. POS0148\u2005Therapeutic drug monitoring for precision medicine and dose optimization of upadacitinib: a real-world prospective observational study. Ann Rheum Dis. 2025;84:437.","journal-title":"Ann Rheum Dis"},{"key":"803_CR72","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1007\/s10620-024-08630-3","volume":"69","author":"T Odah","year":"2024","unstructured":"Odah T, Karime C, Desai A, Picco MF, Kinnucan JA, Hashash JG, et al. Response to Upadacitinib in patients with inflammatory bowel disease previously treated with Tofacitinib. Dig Dis Sci. 2024;69:3911\u20139.","journal-title":"Dig Dis Sci"},{"key":"803_CR73","doi-asserted-by":"publisher","first-page":"e01673","DOI":"10.14309\/crj.0000000000001673","volume":"12","author":"M Chatto","year":"2025","unstructured":"Chatto M, Jairath V. Upadacitinib monotherapy after Tofacitinib failure was successful for induction but not maintenance of remission in medically refractory ulcerative colitis. ACG Case Rep J. 2025;12:e01673.","journal-title":"ACG Case Rep J"},{"key":"803_CR74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"GBD 2017 Inflammatory Bowel Disease Collaborators","year":"2020","unstructured":"GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and National burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:17\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"803_CR75","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1080\/13696998.2024.2333683","volume":"27","author":"M Saruta","year":"2024","unstructured":"Saruta M, Kawaguchi I, Ogawa Y, Sanchez Gonzalez Y, Numajiri N, Tang X, et al. Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in japan: a cost per responder analysis of Upadacitinib. J Med Econ. 2024;27:566\u201374.","journal-title":"J Med Econ"},{"key":"803_CR76","doi-asserted-by":"publisher","first-page":"101091","DOI":"10.1016\/j.vhri.2025.101091","volume":"46","author":"C Tzanetakos","year":"2025","unstructured":"Tzanetakos C, Psarra M, Kotsis I, Gourzoulidis G. Cost-Effectiveness analysis of Upadacitinib in patients with moderately to severely active ulcerative colitis in Greece. Value Health Reg Issues. 2025;46:101091.","journal-title":"Value Health Reg Issues"},{"key":"803_CR77","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1177\/2050640620977405","volume":"9","author":"S Festa","year":"2021","unstructured":"Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, et al. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. United Eur Gastroenterol J. 2021;9:507\u201316.","journal-title":"United Eur Gastroenterol J"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00803-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00803-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00803-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:07:16Z","timestamp":1768342036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00803-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00803-9","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}